Bank of America upped its price target for Vertex Pharmaceuticals from $555 to $567, signaling growing confidence in the ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.
Homes and Gardens on MSN1d
It's your last chance to buy one of our all-time favorite Shark upright vacuums in the Walmart sale – I'm a vacuum tester, and it's a seriously worthy upgradeShark is our go-to brand for upright vacuums, with their range of powerful and truly useful vacuums dominating the upright ...
In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
One Redditor shared how they found a high-quality Shark Vertex vacuum cleaner in the trash and got it for free.
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...
Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...
SpotDraft, a contract lifecycle management (CLM) platform, has recently raised $54 million in its Series B round led by ...
Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback